CXCR2 and colitis: Recently, Katoh et al. [29] reported that the inhibition of CXCR2+ MDSC recruitment into colonic mucosa and tumors dramatically suppress colonic inflammation, suggesting that CXCR2+ MDSCs are essential for colitis-associated cancer.